基本信息
views: 346
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Di Bisceglie’s research has focused on hepatitis B and hepatitis C viral infections, which can cause fibrosis and cirrhosis, as well as other complications that may lead to liver cancer and death.
From discovery of the hepatitis C virus in 1989 to the advent of new drugs that can cure the illness, Di Bisceglie has been a driving force in the remarkable progress that has been made in treating viral hepatitis.
In South Africa, Di Bisceglie was a member of the first team to use recombinant alpha interferon to treat hepatitis B. At the NIH, he helped develop alpha interferon as a therapy for chronic hepatitis C. Di Bisceglie was the first to test ribavirin as a therapy for chronic hepatitis C.
From discovery of the hepatitis C virus in 1989 to the advent of new drugs that can cure the illness, Di Bisceglie has been a driving force in the remarkable progress that has been made in treating viral hepatitis.
In South Africa, Di Bisceglie was a member of the first team to use recombinant alpha interferon to treat hepatitis B. At the NIH, he helped develop alpha interferon as a therapy for chronic hepatitis C. Di Bisceglie was the first to test ribavirin as a therapy for chronic hepatitis C.
Research Interests
Papers共 494 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Eric B. Cohen,Arie Regev, Anju Garg,Adrian M. Di Bisceglie,James H. Lewis,John M. Vierling,Judith Hey-Hadavi, Klaudia Steplewski, Anna Fettiplace,Chunlin L. Chen, Nonko Pehlivanov,Stuart Kendrick,
Drug safety (2024)
crossref(2023)
ALIMENTARY PHARMACOLOGY & THERAPEUTICSno. 4 (2023): 482-483
Cited0Views0Bibtex
0
0
Journal of hepatologyno. 3 (2022): 754-754
Load More
Author Statistics
#Papers: 491
#Citation: 38235
H-Index: 91
G-Index: 190
Sociability: 8
Diversity: 3
Activity: 45
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn